Literature DB >> 24021858

SOD1-G93A mice exhibit muscle-fiber-type-specific decreases in glucose uptake in the absence of whole-body changes in metabolism.

Susan E Smittkamp1, Jill K Morris, Gregory L Bomhoff, Mark E Chertoff, Paige C Geiger, John A Stanford.   

Abstract

BACKGROUND: Skeletal muscles play an important role in systemic glucose homeostasis and are purported to be the origin of the altered metabolic state observed in amyotrophic lateral sclerosis (ALS).
OBJECTIVE: The purpose of this study was to evaluate whole-body and muscle-specific glucose metabolism in the SOD1-G93A mouse model of ALS.
METHODS: We assessed glucose tolerance in early-, middle-, and late-stage SOD1-G93A and control mice using an intraperitoneal glucose tolerance test. We then measured the respiratory exchange ratio (CO2 production/O2 consumption) as a function of fasting and feeding using indirect calorimetry in a subset of male mice at these time points. Finally, muscles from all mice were harvested to evaluate basal and insulin-stimulated glucose transport in fast- and slow-twitch muscles.
RESULTS: No changes in systemic glucose clearance were observed in SOD1-G93A mice at any stage, nor were there changes in fasting insulin levels. Indirect calorimetry revealed an increase in the respiratory exchange ratio during the fed state at middle, but not at early or late stages of disease. Middle-stage SOD1-G93A mice exhibited decreased insulin-stimulated glucose uptake in fast-twitch, but not slow-twitch, skeletal muscle. Late-stage SOD1-G93A mice exhibited decreased insulin-stimulated glucose uptake in both fast- and slow-twitch muscle, as well as increased basal (non-insulin-stimulated) glucose uptake.
CONCLUSIONS: These results suggest that alterations in muscle metabolism occur in a fiber-type-specific manner in ALS, but do not necessarily lead to whole-body metabolic changes in SOD1-G93A mice.
Copyright © 2013 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24021858      PMCID: PMC3970434          DOI: 10.1159/000351606

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  51 in total

Review 1.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

2.  Wild-type human SOD1 overexpression does not accelerate motor neuron disease in mice expressing murine Sod1 G86R.

Authors:  Jean-Nicolas Audet; Geneviève Gowing; Jean-Pierre Julien
Journal:  Neurobiol Dis       Date:  2010-06-02       Impact factor: 5.996

3.  Selective changes in mitochondria respiratory properties in oxidative or glycolytic muscle fibers isolated from G93AhumanSOD1 transgenic mice.

Authors:  N Leclerc; F Ribera; J Zoll; J M Warter; P Poindron; E Lampert; J Borg
Journal:  Neuromuscul Disord       Date:  2001-11       Impact factor: 4.296

4.  Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis.

Authors:  J C Desport; P M Preux; L Magy; Y Boirie; J M Vallat; B Beaufrère; P Couratier
Journal:  Am J Clin Nutr       Date:  2001-09       Impact factor: 7.045

5.  RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis.

Authors:  T Canton; G A Böhme; A Boireau; F Bordier; S Mignani; P Jimonet; G Jahn; M Alavijeh; J Stygall; S Roberts; C Brealey; M Vuilhorgne; M W Debono; S Le Guern; M Laville; D Briet; M Roux; J M Stutzmann; J Pratt
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

6.  Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases.

Authors:  D Frey; C Schneider; L Xu; J Borg; W Spooren; P Caroni
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

Review 7.  IRS proteins and the common path to diabetes.

Authors:  Morris F White
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-09       Impact factor: 4.310

8.  Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families.

Authors:  Takayo Arisato; Ryuichi Okubo; Hitoshi Arata; Koji Abe; Kei Fukada; Saburo Sakoda; Akira Shimizu; Xing Hui Qin; Shuji Izumo; Mitsuhiro Osame; Masanori Nakagawa
Journal:  Acta Neuropathol       Date:  2003-09-27       Impact factor: 17.088

9.  Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1(G93A G1H) mouse model of familial amyotrophic lateral sclerosis.

Authors:  Michael F Azari; Elizabeth C Lopes; Chantelle Stubna; Bradley J Turner; Dawei Zang; Nicos A Nicola; John B Kurek; Surindar S Cheema
Journal:  Brain Res       Date:  2003-08-22       Impact factor: 3.252

10.  Assessing disease onset and progression in the SOD1 mouse model of ALS.

Authors:  Patrick Weydt; So Yon Hong; Michel Kliot; Thomas Möller
Journal:  Neuroreport       Date:  2003-05-23       Impact factor: 1.837

View more
  9 in total

1.  Diaphragm neuromuscular transmission failure in aged rats.

Authors:  Matthew J Fogarty; Maria A Gonzalez Porras; Carlos B Mantilla; Gary C Sieck
Journal:  J Neurophysiol       Date:  2019-05-01       Impact factor: 2.714

2.  Defective daily temperature regulation in a mouse model of amyotrophic lateral sclerosis.

Authors:  Maurine C Braun; Alexandra Castillo-Ruiz; Premananda Indic; Dae Young Jung; Jason K Kim; Robert H Brown; Steven J Swoap; William J Schwartz
Journal:  Exp Neurol       Date:  2018-07-18       Impact factor: 5.330

3.  A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis.

Authors:  Lavinia Palamiuc; Anna Schlagowski; Shyuan T Ngo; Aurelia Vernay; Sylvie Dirrig-Grosch; Alexandre Henriques; Anne-Laurence Boutillier; Joffrey Zoll; Andoni Echaniz-Laguna; Jean-Philippe Loeffler; Frédérique René
Journal:  EMBO Mol Med       Date:  2015-05       Impact factor: 12.137

4.  A(a)LS: Ammonia-induced amyotrophic lateral sclerosis.

Authors:  Bhavin Parekh
Journal:  F1000Res       Date:  2015-05-14

5.  Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset.

Authors:  Harper S Kim; John Son; Donghwan Lee; Joy Tsai; Danny Wang; E Sandra Chocron; Seongwoo Jeong; Pamela Kittrell; Charles F Murchison; Richard E Kennedy; Alejandro Tobon; Carlayne E Jackson; Andrew M Pickering
Journal:  BMC Neurol       Date:  2022-02-21       Impact factor: 2.903

6.  Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis.

Authors:  Débora Lanznaster; Clément Bruno; Jérôme Bourgeais; Patrick Emond; Ilyess Zemmoura; Antoine Lefèvre; Pascal Reynier; Sébastien Eymieux; Emmanuelle Blanchard; Patrick Vourc'h; Christian R Andres; Salah Eddine Bakkouche; Olivier Herault; Luc Favard; Philippe Corcia; Hélène Blasco
Journal:  Biomedicines       Date:  2022-06-02

7.  The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis.

Authors:  S T Ngo; F J Steyn
Journal:  Cell Regen (Lond)       Date:  2015-08-27

8.  Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Tesfaye W Tefera; Yide Wong; Mallory E Barkl-Luke; Shyuan T Ngo; Nicola K Thomas; Tanya S McDonald; Karin Borges
Journal:  PLoS One       Date:  2016-08-26       Impact factor: 3.240

9.  Specific Physical Exercise Improves Energetic Metabolism in the Skeletal Muscle of Amyotrophic-Lateral- Sclerosis Mice.

Authors:  Céline Desseille; Séverine Deforges; Olivier Biondi; Léo Houdebine; Domenico D'amico; Antonin Lamazière; Cédric Caradeuc; Gildas Bertho; Gaëlle Bruneteau; Laure Weill; Jean Bastin; Fatima Djouadi; François Salachas; Philippe Lopes; Christophe Chanoine; Charbel Massaad; Frédéric Charbonnier
Journal:  Front Mol Neurosci       Date:  2017-10-20       Impact factor: 5.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.